The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.
Clascoterone won't be available in the US until 2028, with EU filings planned for 2027. It's considered an alternative for those who experience side effects from standard treatments like finasteride and dutasteride.
The conversation discusses the importance of scalp skin barrier health in hair follicle cycling, suggesting treatments like ceramides or niacinamide to support hair growth. It also mentions the use of finasteride for hair loss.
The conversation discusses using topical synthetic prostaglandins like Bimatoprost, Latanoprost, and cetirizine for hair growth. The user shares a link suggesting these treatments may be effective.
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
The conversation discusses hair regrowth using Scandinavian Biolabs products, biotin pills, a dermaroller, rosemary oil, and a silicone head cleaner. The user observes weak hair regrowth and seeks opinions on the results.
People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.
The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.
The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
Copper peptides GHK-Cu and AHK-Cu are discussed for hair loss treatment, with questions about their effectiveness and application methods. One user suggests sticking to traditional treatments like Minoxidil and Finasteride, as they didn't notice significant results with copper peptides.
Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.
Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.
Some users report encouraging results with laser caps for hair loss, while others see no improvement. Treatments mentioned include low-level laser therapy, Minoxidil, and finasteride.
Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.
The conversation is about obtaining alfatradiol in Canada, specifically in Quebec, and whether it requires a prescription or can be bought online. A user suggests ordering it from a specific website.
Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.
The conversation discusses using alfatradiol, a weaker estrogen, as a treatment for hair loss, with some users sharing their experiences and challenges in obtaining it. One user mentions using a topical solution containing alfatradiol, cetricin, caffeine, and melatonin, noting no significant hair growth but stabilization.
The conversation discusses combining Breezula with Minoxidil for hair loss treatment, with some users suggesting it could be used alongside finasteride. There is interest in the potential effectiveness and side effects of this combination.
The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.
PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.
The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.
Prolactin may contribute to hair loss, but targeting its receptor won't cure androgenetic alopecia. ABS-201 could be a useful alternative or adjuvant therapy, similar to JAK inhibitors, but not more effective than HMI-115.